🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the fight against increasingly resistant strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting in excess of 82 million new cases per year. Notably increased rates are seen in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Testing Results and Global Access

According to data published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an equal footing with the current standard treatment, which uses an injection and a pill. The trial enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Clinicians treating patients have shared positive views. The availability of a easy-to-administer therapy of this kind is described as a "revolutionary step" for managing the epidemic. This is viewed as crucial to lessen the impact of the illness for individuals and to stop the proliferation of untreatable gonorrhoea around the world.